Literature DB >> 35768638

Contribution of schizophrenia polygenic burden to longitudinal phenotypic variance in 22q11.2 deletion syndrome.

Maris Alver1,2,3, Valentina Mancini4, Kristi Läll5, Maude Schneider4,6, Luciana Romano7, Reedik Mägi5, Emmanouil T Dermitzakis7, Stephan Eliez7,4, Alexandre Reymond8.   

Abstract

While the recurrent 22q11.2 deletion is one of the strongest genetic risk factors for schizophrenia (SCZ), variability of its associated neuropsychiatric endophenotypes reflects its incomplete penetrance for psychosis development. To assess whether this phenotypic variability is linked to common variants associated with SCZ, we studied the association between SCZ polygenic risk score (PRS) and longitudinally acquired phenotypic information of the Swiss 22q11.2DS cohort (n = 97, 50% females, mean age 17.7 yr, mean visit interval 3.8 yr). The SCZ PRS with the best predictive performance was ascertained in the Estonian Biobank (n = 201,146) with LDpred. The infinitesimal SCZ PRS model showed the strongest capacity in discriminating SCZ cases from controls with one SD difference in SCZ PRS corresponding to an odds ratio (OR) of 1.73 (95% CI 1.57-1.90, P = 1.47 × 10-29). In 22q11.2 patients, random-effects ordinal regression modelling using longitudinal data showed SCZ PRS to have the strongest effect on social anhedonia (OR = 2.09, P = 0.0002), and occupational functioning (OR = 1.82, P = 0.0003) within the negative symptoms course, and dysphoric mood (OR = 2.00, P = 0.002) and stress intolerance (OR = 1.76, P = 0.0002) within the general symptoms course. Genetic liability for SCZ was additionally associated with full scale cognitive decline (β = -0.25, P = 0.02) and with longitudinal volumetric reduction of the right and left hippocampi (β = -0.28, P = 0.005; β = -0.23, P = 0.02, respectively). Our results indicate that the polygenic contribution to SCZ acts upon the threshold-lowering first hit (i.e., the deletion). It modifies the endophenotypes of 22q11.2DS and augments the derailment of developmental trajectories of negative and general symptoms, cognition, and hippocampal volume.
© 2022. The Author(s).

Entities:  

Year:  2022        PMID: 35768638     DOI: 10.1038/s41380-022-01674-9

Source DB:  PubMed          Journal:  Mol Psychiatry        ISSN: 1359-4184            Impact factor:   13.437


  80 in total

Review 1.  The 22q11.2 deletion syndrome as a window into complex neuropsychiatric disorders over the lifespan.

Authors:  Rachel K Jonas; Caroline A Montojo; Carrie E Bearden
Journal:  Biol Psychiatry       Date:  2013-08-28       Impact factor: 13.382

Review 2.  Copy number variants, diseases and gene expression.

Authors:  Charlotte N Henrichsen; Evelyne Chaignat; Alexandre Reymond
Journal:  Hum Mol Genet       Date:  2009-04-15       Impact factor: 6.150

3.  Prevalence of rearrangements in the 22q11.2 region and population-based risk of neuropsychiatric and developmental disorders in a Danish population: a case-cohort study.

Authors:  Line Olsen; Thomas Sparsø; Shantel M Weinsheimer; Marcelo Bertalan Quintanilha Dos Santos; Wiktor Mazin; Anders Rosengren; Xabier Calle Sanchez; Louise K Hoeffding; Henriette Schmock; Marie Baekvad-Hansen; Jonas Bybjerg-Grauholm; Mark J Daly; Benjamin M Neale; Marianne G Pedersen; Esben Agerbo; Ole Mors; Anders Børglum; Merete Nordentoft; David M Hougaard; Preben Bo Mortensen; Daniel H Geschwind; Carsten Pedersen; Wesley K Thompson; Thomas Werge
Journal:  Lancet Psychiatry       Date:  2018-06-07       Impact factor: 27.083

Review 4.  22q11.2 deletion syndrome.

Authors:  Donna M McDonald-McGinn; Kathleen E Sullivan; Bruno Marino; Nicole Philip; Ann Swillen; Jacob A S Vorstman; Elaine H Zackai; Beverly S Emanuel; Joris R Vermeesch; Bernice E Morrow; Peter J Scambler; Anne S Bassett
Journal:  Nat Rev Dis Primers       Date:  2015-11-19       Impact factor: 52.329

5.  Copy number variations and cognitive phenotypes in unselected populations.

Authors:  Katrin Männik; Reedik Mägi; Aurélien Macé; Ben Cole; Anna L Guyatt; Hashem A Shihab; Anne M Maillard; Helene Alavere; Anneli Kolk; Anu Reigo; Evelin Mihailov; Liis Leitsalu; Anne-Maud Ferreira; Margit Nõukas; Alexander Teumer; Erika Salvi; Daniele Cusi; Matt McGue; William G Iacono; Tom R Gaunt; Jacques S Beckmann; Sébastien Jacquemont; Zoltán Kutalik; Nathan Pankratz; Nicholas Timpson; Andres Metspalu; Alexandre Reymond
Journal:  JAMA       Date:  2015-05-26       Impact factor: 56.272

6.  Cognitive decline preceding the onset of psychosis in patients with 22q11.2 deletion syndrome.

Authors:  Jacob A S Vorstman; Elemi J Breetvelt; Sasja N Duijff; Stephan Eliez; Maude Schneider; Maria Jalbrzikowski; Marco Armando; Stefano Vicari; Vandana Shashi; Stephen R Hooper; Eva W C Chow; Wai Lun Alan Fung; Nancy J Butcher; Donald A Young; Donna M McDonald-McGinn; Annick Vogels; Therese van Amelsvoort; Doron Gothelf; Ronnie Weinberger; Abraham Weizman; Petra W J Klaassen; Sanne Koops; Wendy R Kates; Kevin M Antshel; Tony J Simon; Opal Y Ousley; Ann Swillen; Raquel E Gur; Carrie E Bearden; René S Kahn; Anne S Bassett
Journal:  JAMA Psychiatry       Date:  2015-04       Impact factor: 21.596

7.  A 600 kb deletion syndrome at 16p11.2 leads to energy imbalance and neuropsychiatric disorders.

Authors:  Flore Zufferey; Elliott H Sherr; Noam D Beckmann; Ellen Hanson; Anne M Maillard; Loyse Hippolyte; Aurélien Macé; Carina Ferrari; Zoltán Kutalik; Joris Andrieux; Elizabeth Aylward; Mandy Barker; Raphael Bernier; Sonia Bouquillon; Philippe Conus; Bruno Delobel; W Andrew Faucett; Robin P Goin-Kochel; Ellen Grant; Louise Harewood; Jill V Hunter; Sébastien Lebon; David H Ledbetter; Christa Lese Martin; Katrin Männik; Danielle Martinet; Pratik Mukherjee; Melissa B Ramocki; Sarah J Spence; Kyle J Steinman; Jennifer Tjernagel; John E Spiro; Alexandre Reymond; Jacques S Beckmann; Wendy K Chung; Sébastien Jacquemont
Journal:  J Med Genet       Date:  2012-10       Impact factor: 6.318

8.  Epilepsy and Other Neuropsychiatric Manifestations in Children and Adolescents with 22q11.2 Deletion Syndrome.

Authors:  Eun Hee Kim; Mi Sun Yum; Beom Hee Lee; Hyo Won Kim; Hyun Jeoung Lee; Gu Hwan Kim; Yun Jeong Lee; Han Wook Yoo; Tae Sung Ko
Journal:  J Clin Neurol       Date:  2016-01       Impact factor: 3.077

9.  Defining the Effect of the 16p11.2 Duplication on Cognition, Behavior, and Medical Comorbidities.

Authors:  Debra D'Angelo; Sébastien Lebon; Qixuan Chen; Sandra Martin-Brevet; LeeAnne Green Snyder; Loyse Hippolyte; Ellen Hanson; Anne M Maillard; W Andrew Faucett; Aurélien Macé; Aurélie Pain; Raphael Bernier; Samuel J R A Chawner; Albert David; Joris Andrieux; Elizabeth Aylward; Genevieve Baujat; Ines Caldeira; Philippe Conus; Carrina Ferrari; Francesca Forzano; Marion Gérard; Robin P Goin-Kochel; Ellen Grant; Jill V Hunter; Bertrand Isidor; Aurélia Jacquette; Aia E Jønch; Boris Keren; Didier Lacombe; Cédric Le Caignec; Christa Lese Martin; Katrin Männik; Andres Metspalu; Cyril Mignot; Pratik Mukherjee; Michael J Owen; Marzia Passeggeri; Caroline Rooryck-Thambo; Jill A Rosenfeld; Sarah J Spence; Kyle J Steinman; Jennifer Tjernagel; Mieke Van Haelst; Yiping Shen; Bogdan Draganski; Elliott H Sherr; David H Ledbetter; Marianne B M van den Bree; Jacques S Beckmann; John E Spiro; Alexandre Reymond; Sébastien Jacquemont; Wendy K Chung
Journal:  JAMA Psychiatry       Date:  2016-01       Impact factor: 21.596

Review 10.  Psychiatric disorders from childhood to adulthood in 22q11.2 deletion syndrome: results from the International Consortium on Brain and Behavior in 22q11.2 Deletion Syndrome.

Authors:  Maude Schneider; Martin Debbané; Anne S Bassett; Eva W C Chow; Wai Lun Alan Fung; Marianne van den Bree; Michael Owen; Kieran C Murphy; Maria Niarchou; Wendy R Kates; Kevin M Antshel; Wanda Fremont; Donna M McDonald-McGinn; Raquel E Gur; Elaine H Zackai; Jacob Vorstman; Sasja N Duijff; Petra W J Klaassen; Ann Swillen; Doron Gothelf; Tamar Green; Abraham Weizman; Therese Van Amelsvoort; Laurens Evers; Erik Boot; Vandana Shashi; Stephen R Hooper; Carrie E Bearden; Maria Jalbrzikowski; Marco Armando; Stefano Vicari; Declan G Murphy; Opal Ousley; Linda E Campbell; Tony J Simon; Stephan Eliez
Journal:  Am J Psychiatry       Date:  2014-06       Impact factor: 18.112

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.